A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
New Trading Symbol "NAYA" Effective Tuesday October 22, 2024SARASOTA, Fla. and MIAMI, Oct. 21, 2024 -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases...
Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseasesSARASOTA, Fla. and MIAMI, Oct. 14, 2024 -- INVO Bioscience ("INVO") (NASDAQ: INVO) today announced it has closed its merger with NAYA...
SARASOTA, Fla., Aug. 14, 2024 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment and acquisition of fertility clinics, and with the...
353% Revenue Growth with improvement in Adjusted EBITDASARASOTA, Fla., May 15, 2024 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the...
SARASOTA, Fla., April 16, 2024 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and...
Abstract from 2023 American Society of Hematology (ASH) MeetingData demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supports initiation of clinical trials in 2024NAYA expects to close its previously announced merger...
NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA's FLEX-NK™ bispecific antibodies and ONK's optimally engineered natural killer (NK) cells for the treatment of cancerPartnership...
SARASOTA, Fla., Nov. 28, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture...
Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla., Nov. 13, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO)...
SARASOTA, Fla. and AVENTURA, Fla., Nov. 10, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc. ("NAYA"), a company dedicated to...